Experts talk about S.C.O.P.E.

Dr. Kane served as Chair of Psychiatry at Zucker Hillside Hospital for 34 years and Chair of Psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York for 12 years.

He earned his medical degree from New York University in New York, New York, and completed his internship and residency in psychiatry at Zucker Hillside Hospital. He is a Diplomate of the American Board of Psychiatry and Neurology.

Dr. Kane is the recipient of many awards, including the Lieber Prize, the APA’s Kempf Fund Award and APA Foundation Prize, the New York State Office of Mental Health Lifetime Achievement Award, and the American College of Psychiatrists Dean Award. He has served as President of the American Society of Clinical Psychopharmacology, the Psychiatry Research Society, and the Schizophrenia International Research Society.

He has been a principal investigator on 23 National Institutes of Health (NIH) grants focusing on schizophrenia, psychobiology and treatment, recovery, and quality and cost of care. He is the author of more than 925 peer-reviewed papers and has been consistently ranked in the top 1% of researchers in his field, by Thomas Reuters based on citations of his work.

Dr. Kane has served on the Board of Scientific Counselors for the National Institute of Mental Health (NIMH) and chaired the Psychopharmacologic Drugs Advisory Committee of the FDA, and serves on the editorial boards of numerous journals.

Board certifications

Psychiatry - American Board of Psychiatry/Neurology-Psychiatry

Leslie Citrome, MD, MPH, is clinical professor of psychiatry and behavioral sciences at New York Medical College in Valhalla, New York, a clinical professor of psychiatry at SUNY Upstate Medical University, and an adjunct clinical professor of psychiatry at the Icahn School of Medicine at Mount Sinai in New York City. He is a Distinguished Life Fellow of the American Psychiatric Association and a Fellow of the American Society of Clinical Psychopharmacology, where he currently serves as Immediate Past President. In addition to his academic positions, he has a private practice in psychiatry in Pomona, New York, and is a volunteer consultant to the Assertive Community Treatment team/Mental Health Association of Rockland County.

Dr. Citrome obtained his MD degree from the McGill University Faculty of Medicine in 1983 and his MPH degree from the Columbia School of Public Health in 1996. His immediate prior position was as the founding Director of the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York, where he worked from 1994 through 2010 and achieved the rank of Professor of Psychiatry at the New York University School of Medicine.

Dr. Citrome is currently a consultant in clinical trial design and interpretation. He is a frequent lecturer on the quantitative assessment of clinical trial results, including the metrics of number needed to treat and number needed to harm, and he has lectured throughout the Americas, Europe, Asia, and Australasia.

Dr. Citrome’s main interests include schizophrenia, bipolar disorder, and major depressive disorder. He is author or co-author of more than 600 research reports, reviews, and chapters in the scientific literature. Dr. Citrome is a member of the Board of Directors of the World Association of Medical Editors and editor-in-chief of Current Medical Research and Opinion (CMRO), published by Taylor & Francis; editor emeritus of the International Journal of Clinical Practice where he was editor-in-chief 2013-2019; psychiatry topic editor for Clinical Therapeutics; editor of the American Society of Clinical Psychopharmacology Corner in the Journal of Clinical Psychiatry; section editor for psychopharmacology for Current Psychiatry; and an editorial board member for several other journals.

• Professor, Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
• Professor and Chair, Department of Child and Adolescent Psychiatry at Charité- University Medicine, Berlin, Germany.

Christoph Correll, MD, completed his medical studies at the Free University of Berlin in Germany and Dundee Medical School in Scotland. Dr. Correll is board certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at Zucker Hillside Hospital in New York City. Since 1997, Dr. Correll has been conducting research in New York, and in 2017 he began working in Germany again.

Professor Correll’s work focuses on the early identification and treatment of youth and adults with severe mental illness, clinical trials, epidemiology, psychopharmacology, meta-analyses, and the interface between physical health and mental health. He has authored and co-authored more than 900 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, has been the principal investigator and steering committee member of several large, federally funded grants. He has received more than 40 national and international research awards and fellowships for his work. Since 2014, the year of inception of this metric, he has been listed each year by Thomson Reuters/Clarivate/Web of Science as one of the most influential scientific minds and one of the top 1% cited scientists in the area of psychiatry. Additionally, he has been holding numerous Expertscape rankings based on the number of publications and citations in the past 10 years including for 15 topics as “Expert” (among the top 1% cited scientists), and 24 topics as “World Expert” (among the top 0.1% cited scientists) including being ranked as the number one world expert in 9 areas including “central nervous system agents”, “psychotropic drugs”, “schizophrenia”, “schizophrenia spectrum and other psychotic disorders”, “antipsychotics”, “delayed action preparations”, and “weight gain”.

Jose M. Rubio, MD, PhD, is an assistant professor of psychiatry at the Feinstein Institutes for Medical Research and the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, and he is a board-certified psychiatrist and physician-investigator.

Dr. Rubio obtained his MD and PhD from the Universitat de Valencia and Universidad Complutense de Madrid (Spain), respectively, and psychiatry residency at Zucker Hillside Hospital. After completing residency in 2017, he received a Career Development Award from the National Institutes of Health to study biomarker development and relapse in schizophrenia.

As an emerging investigator, Dr. Rubio has published more than 50 articles, focusing on the application of evidence-based interventions in the real world, neuroimaging biomarkers, and the prevention of relapse in schizophrenia. Some of the phenomena that he studies are the underutilization of long-acting injectable antipsychotics, clozapine and the neurobiological mechanisms leading to relapse or decrement in antipsychotic efficacy over time.

Dr. Rubio regularly lectures on the treatment of schizophrenia and serves as a consultant on the interpretation of results from clinical trials. In addition, he supervises residents in a specialized psychosis clinic and co-leads the research track in the Zucker Hillside Hospital psychiatry residency program. Dr. Rubio has received various awards, including the Early Career Investigator Travel Award from the Schizophrenia International Research Society (SIRS) and the American College of Neuropsychopharmacology (ACNP), and the Alkermes Pathways Award for Junior Investigators.